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Introduction 26
There is growing interest in the role of skeletal muscle carnitine and its associated enzymes in 27 the perturbation of muscle lipid metabolism and aetiology of obesity and type 2 diabetes. For 28 example, incomplete or insufficient β-oxidation of fatty acids may precede the accumulation 29 of deleterious lipid intermediates and has been implicated in the development of skeletal 30 muscle insulin resistance (1, 2) . In line with the proposal that skeletal muscle carnitine 31 availability is limiting to CPT1 flux and fatty acid oxidation (3), elevating muscle carnitine 32 content via acute L-carnitine infusion (4) or chronic feeding (5) promotes physiologic and 33 gene expression adaptations that are consistent with enhanced fat oxidation at rest and during 34 moderate-intensity exercise. Conversely during high-intensity exercise, when mitochondrial 35 acetyl-group provision is limited (at least partially) by the activation kinetics of the pyruvate 36 dehydrogenase complex (PDC) enzyme (6) , increasing skeletal muscle carnitine availability 37 and acetylation improves the matching of glycolytic, PDC and mitochondrial substrate fluxes 38 (7) . The latter observation has implications for the enhancement of mitochondrial ATP 39 delivery, such as in disease states where skeletal muscle perfusion may be impaired (8, 9) . 40 
41
Increasing the availability of carnitine within skeletal muscle is, therefore, a useful research 42 tool to investigate the importance of these processes in humans in vivo, as well as to 43 manipulate muscle metabolism for health benefits. However, muscle carnitine accretion, 44 facilitated by the Na + -dependent transporter OCTN2 (10) , occurs against a 100-fold 45 concentration gradient and hence L-carnitine feeding (11, 12) or intravenous infusion (13, 14) 46 alone has no impact upon muscle carnitine content. Simultaneous elevation of plasma 47 carnitine and serum insulin concentrations has proven effective in stimulating muscle 48 carnitine uptake in healthy subjects (4, 14) and as such, a 20% increase in muscle carnitine 49 can be achieved through twice-daily feeding of L-carnitine in a beverage containing 80 g of 50 carbohydrate over a 12-24 week period (5, 7) . However, such a large carbohydrate load per 51 se (160 g/day) will likely affect metabolism and alter body composition (5) and so 52 investigation into alternative oral insulinogenic formulations that can stimulate muscle 53 carnitine accumulation using lower carbohydrate loads is warranted. For example, whey 54 protein has previously been fed with carbohydrate to promote insulin-mediated muscle 55 creatine retention (15) and, unlike carbohydrate, prolonged protein supplementation is less 56 likely to influence body fat content (16) . Therefore, the aim of the present study was to 57 acutely assess forearm net carnitine balance (NCB) and uptake following oral L-carnitine 58 ingestion in combination with 80 g of carbohydrate alone versus a protein-carbohydrate blend 59 that would produce a similar serum insulin response.
Subjects and Methods 61
Volunteers 62
Seven healthy, non-vegetarian males (age 24.2 ± 5.0 yrs, BMI 23.3 ± 3.1 kg·m -2 ) gave 63 written informed consent and attended a routine medical screening prior to starting the study, 64 which was approved by the University of Nottingham Medical School Ethics Committee. 65
66

Experimental Protocol 67
Subjects completed three single-blind, randomised (randomization.com) visits (Figure 1 ) 68 following a 10 hour fast. Upon arrival at the University of Nottingham David Greenfield 69
Physiology Unit, volunteers voided their bladder and laid semi-supine with one hand heated 70 to ~55°C in an air-warming unit. This method has been shown to arterialise venous blood to 71 within 3% of the oxygen saturation values of arterial blood (17) . A cannula was placed 72 retrograde into a dorsal vein of the heated hand for arterialised-venous blood sampling and 73 into a deep-lying antecubital vein of the contralateral arm to sample venous blood draining 74 the forearm muscle bed (18, 19 Based on our previous carnitine feeding and infusion studies (25, 26) , this study was powered 120 at 80% to detect a 10% difference in NCB in 7 subjects with an alpha level of 0.05. Time 121 dependent variables (serum insulin and plasma free concentrations, plasma flow, NCB, 122 carnitine extraction, MPE, Rd and Ra) were analysed using two-way repeated measures 123 analysis of variance (ANOVA) with Bonferoni-corrected paired t-test to isolate main effects 124 post-hoc. Urinary carnitine excretion and AUC were compared using one-way ANOVA with 125 Tukey post-hoc. All statistical analyses were performed with GraphPad Prism 6 (GraphPad 126 Software). Data presented are mean ± standard error of the mean (SE) for seven subjects.
Results 128
Serum Insulin and glucose extraction 129
Serum insulin concentration was similar between CON, CHO and CHO-PRO at 0 min (7 ± 2, 130 5 ± 1 and 6 ± 1 mU•L -1 , respectively) and did not change during CON (Figure 2A) . Insulin 131 concentration increased rapidly after CHO and CHO-PRO ingestion, peaking at 100 min (64 132 ± 10 and 72 ± 10 mU•L -1 , respectively), and remained elevated above CON thereafter. AUC 133 in CHO (4.5 ± 0.8) and CHO-PRO (3.8 ± 0.6) was 102-and 85-fold greater, respectively, 134 than CON (0.04 ± 0.1 U·L -1 ·min; P<0.01), but no different between CHO and CHO-PRO. An 135 interaction effect was observed (P<0.001) such that glucose extraction during CHO and 136 CHO-PRO was higher than CON from 100-180 minutes and also greater in CHO than CHO-137 PRO at 100 and 140 minutes ( Figure 2B) . Limb/organ balance models normally preclude definitive conclusions on whether substrate 215 uptake, efflux, or a combination of the two has occurred (28) . Here, the use of 2 H3-carnitine 216 tracer enables a more direct interrogation of muscle carnitine uptake. The average rate of 217 forearm carnitine disappearance throughout the CON trial (~9 µmol·kg·hr -1 ) is very similar to 218 estimated rates of basal muscle carnitine uptake (11.6 µmol·kg·hr -1 ) from compartmental 219 modelling of intravenously-administered [ 3 H]-carnitine kinetics (34) . Peak Rd during CHO 220 was numerically 15-fold higher than the equivalent time-point in CON and tended to be 221 greater when compared over the entire treatment period (AUC). It could be argued that 222 increases in NCB and Rd during CHO were related to greater plasma flow. However, 223 carnitine fractional extraction, which does not depend on flow, was also elevated following 224 CHO but not CON, whilst plasma flow was similarly elevated above CON in CHO-PRO 225 (where extraction was unchanged). Moreover, peak carnitine Rd during CHO coincided with 226 peak serum insulin concentration, suggesting that the positive NCB during CHO is more 227 likely attributable to an up-regulation of muscle carnitine transport, rather than plasma flow. 228 Serum insulin responses were similar between CHO and CHO-PRO and importantly, were 229 identical over the period when forearm carnitine balance was elevated in CHO. It was thus 230 surprising that NCB was not similarly increased during CHO-PRO. This apparent inhibition 231 of insulin-stimulated muscle carnitine uptake is supported by the finding that Rd following 232 CHO-PRO was supressed relative to CHO and further reflected by the augmented plasma 233 carnitine compartment and 2-fold greater urinary carnitine excretion in CHO-PRO compared 234 to CHO. As forearm glucose extraction was greater in CHO than CHO-PRO, it might be 235 speculated that the absence of a positive NBC in CHO-PRO was related to differential 236 forearm glucose metabolism. However, the difference between CHO and CHO-PRO glucose 237 extraction relative to CON was small, and thus insufficient to explain the contrasting NCB. 238
Considering the obligate role of the organic novel cation transporter in muscle carnitine 239 accumulation (10, 35) , it seems more plausible that the inhibition of muscle carnitine 240 transport following CHO-PRO be related to OCTN2 activity. Known physiological inhibitors 241 of OCTN2 include acylcarnitines (36) which have been shown to accumulate in response to 242 increased amino acid availability as by-products of excessive amino acid oxidation or 243 incomplete β-oxidation (37) . Indeed, plasma acylcarnitine concentrations during CHO-PRO 244 were elevated throughout the period of hyperinsulinemia and thus, could perhaps be 245 responsible for the inhibition of muscle carnitine uptake. In line with this, plasma 246 acylcarnitines are characteristically elevated in the insulin resistant state (38), a scenario in 247 which muscle carnitine accumulation is purportedly compromised. Alternatively, high rates 248 of insulin-responsive, sodium-dependent amino acid flux could restrict cationic muscle 249 carnitine transport following CHO-PRO (39, 40) , although this cannot be inferred from the 250 current data. Why the uptake of carnitine by skeletal muscle would be inhibited by protein, 251
given the predominant dietary source of carnitine is meat (41) , is somewhat perplexing, 252 though it should be noted that the large bolus of protein ingested in this study is excessive 253 compared to the protein content of a normal mixed meal. Nevertheless, a slow postprandial 254 transport of carnitine into muscle, together with a negligible rate of appearance of carnitine 255 from muscle, is entirely consistent with the stability and slow turnover of the muscle carnitine 256 pool (34) . 257
It has previously been suggested that amino acids could inhibit L-carnitine intestinal 258 absorption (42) . However, the greater urinary and plasma carnitine in CHO-PRO during the 259 current study may provide evidence to the contrary. When compared to CHO, the elevated 260 plasma and urinary carnitine in CHO-PRO can reasonably be accounted for by the estimated 261 difference in muscle carnitine uptake. When comparing CON and CHO-PRO trials however, 262 during which NCB was similarly negligible, the differences in plasma and urinary carnitine 263 would suggest that carnitine absorption was not comparable across all trials. In particular, 264 assuming negligible intracellular release of carnitine during CON and CHO-PRO (Ra was not 265 different from zero), the greater plasma MPE during CHO-PRO likely reflects a greater 266 absorption of exogenous carnitine into the endogenous carnitine pool. Based on previous 267 studies ( [43] [44] [45] , it was expected that a 3 g dose of L-carnitine would saturate intestinal active 268 carnitine transport and thus facilitate equivalent carnitine absorption across all trials. 269 However, and in contrast to the suggestion that amino acids may inhibit intestinal carnitine 270 absorption, these findings infer that protein ingestion may increase co-ingested carnitine 271
absorption. This reconciles with the predominant dietary sources of carnitine and, given the 272 blunting of forearm NCB in CHO-PRO, also implies that the mechanism and regulation of 273 intestinal carnitine absorption is perhaps different from that of skeletal muscle. 
